| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 20054 |
| Drug | Carfilzomib (in combination with daratumumab and dexamethasone) |
| Brand | Kyprolis® |
| Indication | In combination with daratumumab and dexamethasone (CAR+DAR+DEX) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
| Assessment Process | |
| Rapid review commissioned | 08/12/2020 |
| Rapid review completed | 14/01/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of carfilzomib in combination with daratumumab and dexamethasone compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/01/2021 |
| Pre-submission consultation with Applicant | 12/10/2021 |
| Full submission received from Applicant | 17/07/2023 |
| Preliminary review sent to Applicant | 05/03/2024 |
| NCPE assessment re-commenced | 12/04/2024 |
| Factual accuracy sent to Applicant | 07/06/2024 |
| NCPE assessment re-commenced | 17/06/2024 |
| NCPE assessment completed | 03/07/2024 |
| NCPE assessment outcome | The NCPE recommends that carfilzomib (Kyprolis®) in combination with daratumumab and dexamethasone not be considered for reimbursement, for this indication*. |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
